SETDB1 and cancer: The expression of innate immune-related genes and antiviral response genes is upregulated in patients with hypoxic tumors and low SETDB1 expression, suggesting that targeting SETDB1 to derepress TE-related innate immune responses may be a viable strategy for eliminating hypoxic cancer cells.